Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Zulresso® (brexanolone) – Expanded indication
June 16, 2022 - The FDA approved Sage Therapeutics’ Zulresso (brexanolone), for the treatment of postpartum depression (PPD) in patients 15 years and older.
